KORU Medical Systems Inc Dossier - Source-backed chat

KORU Medical Systems Inc

KRMDNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.64

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.96Price as of 2 Oct 2026

Data confidenceNot applicable

Market Cap $136M

Enterprise Value $127.8M

Shares Outstanding 46.3M diluted

Moat Rating None

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

KORU Medical Systems is demonstrating strong commercial momentum, highlighted by a record 22% year-over-year revenue growth in Q1 2026. The company's transition toward sustainable profitability is well underway, with adjusted EBITDA and cash usage nearing breakeven. KORU's strategic expansion beyond its core immunoglobulin (Ig) market into non-Ig therapies (such as deferoxamine and oncology) significantly expands its total addressable market. Backed by a highly recurring revenue model with approximately 60,000 patients on its platform, KORU is well-positioned to capture market share globally, particularly through prefilled syringe conversions in the EU.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.00

Mean target$6.80

High · most bullish analyst$8.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.0015%

Persistent tariff-related charges and elevated production costs compress gross margins below 61%. Delays in clinical trials or slower-than-expected end-user adoption of prefilled syringes in the EU limit international growth, causing the company to miss its full-year cash flow and revenue targets.

Base CaseCentral scenario

$6.8060%

Matches the consensus mean

KORU successfully executes its 2026 guidance, delivering net revenues between $47.5 million and $50.0 million (15% to 22% growth) and maintaining gross margins within the 61% to 63% range. The company achieves positive adjusted EBITDA and positive cash flow for the full year, supported by steady domestic core growth and ongoing clinical trial advancements.

Bull CaseUpside scenario

$8.0025%

Accelerated adoption of prefilled syringe conversions in international markets and rapid FDA clearance of the deferoxamine 510(k) application drive top-line growth above the high end of guidance. Operational leverage improves faster than expected, leading to significant positive cash flow and gross margins exceeding 63%.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Robust top-line growth with Q1 2026 revenue up 22% YoY to $11.8 million.
Highly predictable recurring revenue model supported by a base of ~60,000 patients.
Expanding pipeline with eight active non-Ig drug opportunities, including two in Phase III trials.
Strong international momentum, with International Core revenues growing 35% in Q1 2026.
Clear path to profitability with Q1 2026 adjusted EBITDA near breakeven (-$10k) and minimal cash usage.

Key Investment Risks

Gross margin vulnerability to tariff-related charges and manufacturing cost fluctuations.
High customer and geographic concentration in the subcutaneous immunoglobulin (SCIg) market.
Regulatory risks associated with pending 510(k) clearances and clinical trial timelines.
Leadership transition uncertainty following the retirement of CEO Linda Tharby and the appointment of Adam Kalbermatten as President.

Thesis Invalidation Triggers

Full-year gross margins falling below 60.0% due to unmitigated tariff or production cost pressures.
Failure to achieve positive adjusted EBITDA or positive cash flow by the end of fiscal year 2026.
A significant decline in domestic core consumable volumes or loss of market share to competitors.
Rejection or severe delay of the 510(k) application for the Freedom Infusion System with Deferoxamine.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.